New drug cocktail aims to stop AML from coming back
NCT ID NCT07521124
First seen Apr 12, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests whether a combination of three drugs (chidamide, venetoclax, and azacitidine) can help prevent acute myeloid leukemia (AML) from returning in patients who have already achieved complete remission after initial treatment. About 104 adults aged 18 to 80 will receive the drugs in 28-day cycles for up to 12 cycles. The main goal is to see how long patients stay cancer-free without relapse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) IN REMISSION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technolog
Wuhan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.